The Real-World Logistics of CAR T Therapy: Financial and Practical Considerations

Opinion
Video

Panelists discuss how a patient and their medical team collaborated to evaluate the differences between ide-cel and cilta-cel CAR T therapies to make an informed treatment decision.

Video content above is prompted by the following:

  • Please walk us through the process of shared decision-making between you and your health care team. How did you decide between ide-cel and cilta-cel?
Recent Videos
3 experts in this video
Using bispecific antibodies before or after CAR T-cell therapy in multiple myeloma is an area of education for community oncologists.
Vinay K. Puduvalli, MD, is featured in this series.
3 experts in this video
3 experts in this video
Related Content
ORR, DOR, and Safety Outcomes with Lisaftoclax Combo Were Strong in RRMM

ORR, DOR, and Safety Outcomes with Lisaftoclax Combo Were Strong in RRMM

Dylann Cohn-Emery
December 10th 2024
Article

Lisaftoclax with pomalidomide and dexamethasone elicited positive efficacy and safety outcomes in relapsed/refractory multiple myeloma.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

Samantha Shenoy, NP, MSN
October 14th 2024
Podcast

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Reduction in AEs by Pelabresib With Ruxolitinib in JAK-Naive Myelofibrosis

Reduction in AEs by Pelabresib With Ruxolitinib in JAK-Naive Myelofibrosis

Jonah Feldman
December 10th 2024
Article

Pelabresib and ruxolitinib combination maintains consistent reduction of symptoms and anemia in patients with myelofibrosis.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma

James R. Berenson, MD, FACP
September 30th 2024
Podcast

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Findings from DREAMM-7 support belantamab mafodotin plus bortezomib and dexamethasone as a standard of care in relapsed/refractory multiple myeloma.

Belantamab Mafodotin Regimen Improves OS in R/R Multiple Myeloma

Kristi Rosa
December 10th 2024
Article

Findings from DREAMM-7 support belantamab mafodotin plus bortezomib and dexamethasone as a standard of care in relapsed/refractory multiple myeloma.

General Lifestyle Recommendations for Receiving Talquetamab in Multiple Myeloma

General Lifestyle Recommendations for Receiving Talquetamab in Multiple Myeloma

Samantha Shenoy, NP, MSN
December 10th 2024
Article

Samatha Shenoy, NP, MSN, highlighted lifestyle recommendations to help patients who are receiving talquetamab treatment for multiple myeloma.